Differential effects of Helicobacter pylori eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1722-8.

Abstract

Background and aim: Helicobacter pylori-associated gastritis causes accumulation of reactive oxygen species in the mucosal compartment. This prospective study evaluates DNA oxidative damage in biopsy samples obtained from both the antrum and the gastroesophageal junction (GEJ) before and after H. pylori eradication.

Patients and methods: Thirty-two consecutive H. pylori-positive patients underwent endoscopy with multiple biopsy sampling (i.e., antrum, incisura angularis, fundus, and cardia at the GEJ). After H. pylori eradication, 32 patients underwent a checkup endoscopy (mean interval, 5.7 months); in a subgroup of 13 subjects, a third endoscopy procedure was also performed (mean interval, 18 months). Additional biopsy samples (two from the antrum and two from the GEJ) were used to assess 8-hydroxydeoxyguanosine (8OHdG) levels using both high-pressure liquid chromatography with electrochemical detector and ELISA.

Results: In the antral compartment, no significant modifications of 8OHdG levels were assessed after H. pylori eradication. Conversely, following eradication, 8OHdG levels significantly increased (high-pressure liquid chromatography with electrochemical detector, P = 0.04; ELISA method, P = 0.05) in biopsy samples taken from the GEJ, and a further increase was documented in the subgroup of patients who underwent a third endoscopy (P = 0.01). The increasing trend was more relevant in patients in whom H. pylori-cagA-positive strains were eradicated and in those affected by hiatal hernia.

Conclusions: The levels of DNA adducts in the antral mucosa are not modified by H. pylori eradication; conversely, H. pylori eradication significantly increases the oxidative adducts at the GEJ. The clinical and biological importance of this situation and whether and how it relates to a higher risk of precancerous lesions is open to debate.

Publication types

  • Clinical Trial

MeSH terms

  • Anti-Ulcer Agents / therapeutic use*
  • DNA Adducts / drug effects
  • DNA Adducts / isolation & purification
  • DNA Damage
  • Esophageal Diseases / drug therapy*
  • Esophageal Diseases / microbiology
  • Esophageal Diseases / pathology
  • Esophagogastric Junction / microbiology*
  • Female
  • Gastritis / drug therapy*
  • Gastritis / microbiology
  • Gastritis / pathology
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / metabolism
  • Helicobacter Infections / pathology
  • Helicobacter pylori*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / therapeutic use*
  • Prospective Studies
  • Pyloric Antrum / microbiology*

Substances

  • Anti-Ulcer Agents
  • DNA Adducts
  • Omeprazole